Real-world outcomes of pembrolizumab plus carboplatin plus paclitaxel or nab-paclitaxel in non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Tabah, Ashley
Huggar, David
Kish, Jonathan
Bapat, Bela
Liassou, Djibril
Gajra, Ajeet
Miller, Talia
Copher, Ronda
Patel, Manali, I
机构：
[1] Bristol Myers Squibb, Summit, NJ USA
[2] Cardinal Hlth, Dublin, OH USA
[3] SUNY Upstate Med Univ, Syracuse, NY 13210 USA
[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21717
引用
收藏
页数：2
相关论文
共 50 条
  • [31] First-Line Nivolumab plus Nab-Paclitaxel plus Carboplatin (C) in Advanced NSCLC
    Waterhouse, David
    Derosa, William
    Fraser, Cindy Duval
    Gutierrez, Martin
    Ko, Amy
    Ong, Teng Jin
    Pierce, Daniel
    Stergiopoulos, Sotirous
    Kelly, Karen
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S427 - S428
  • [32] UTILIZATION AND COST OF SUPPORTIVE CARE AMONG PATIENTS RECEIVING NAB-PACLITAXEL plus CARBOPLATIN VERSUS SB-PACLITAXEL plus CARBOPLATIN AS FIRST-LINE TREATMENT FOR METASTATIC NON-SMALL CELL LUNG CANCER
    Patel, M.
    Ni, Q.
    VALUE IN HEALTH, 2016, 19 (03) : A155 - A155
  • [33] nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis
    Langer, Corey J.
    Gajra, Ajeet
    Gridelli, Cesare
    Konduri, Kartik
    Morgensztern, Daniel
    Spigel, David
    Talbot, Denis
    Thomas, Michael
    Weiss, Jared
    Pilot, Richard
    Bhore, Rafia
    Wolfsteiner, Marianne
    Ong, Teng Jin
    Socinski, Mark
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [34] Analysis of Outcomes in Diabetic Patients in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
    Hirsh, V.
    Owen, S. P.
    Ko, A.
    Renschler, M.
    Socinski, M. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S21 - S21
  • [35] nab-Paclitaxel plus Carboplatin in Advanced NSCLC: Analysis of Age and Renal Function
    Bernicker, Eric
    Langer, Corey J.
    Ko, Amy
    Ong, Teng Jin
    Socinski, Mark A.
    O'Brien, Mary E. R.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S544 - S544
  • [36] Nivolumab (nivo) plus nab-paclitaxel (nab-P) plus carboplatin (C) in patients (pts) with non-small cell lung cancer (NSCLC): Interim results from a multicenter phase I study.
    Waterhouse, David Michael
    Goldman, Jonathan Wade
    George, Ben
    O'Dwyer, Peter J.
    Ye, Moncy
    Chen, Tianlei
    Trunova, Nataliya
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] IgA vasculitis induced by carboplatin plus nab-paclitaxel plus pembrolizumab in a patient with advanced lung squamous cell carcinoma: a case report
    Terashima, Yuto
    Matsumoto, Masaru
    Ozaki, Saeko
    Nakagawa, Michiko
    Nakagome, Shun
    Terasaki, Yasuhiro
    Iida, Hiroki
    Mitsugi, Ryotaro
    Kuramochi, Eri
    Okada, Naoko
    Inoue, Tomoyasu
    Matsuki, Satoru
    Kitagawa, Shingo
    Fukuizumi, Aya
    Onda, Naomi
    Takeuchi, Susumu
    Miyanaga, Akihiko
    Kasahara, Kazuo
    Seike, Masahiro
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [38] Real-World Data Comparing Cisplatin/Vinorelbine and Carboplatin/Paclitaxel in Concurrent Chemoradiation for Non-Small Cell Lung Cancer (NSCLC): Safety and Outcomes
    Chan, Christopher Wei En
    Abdelaziz, Noha
    Makady, Nafie Faisal
    LUNG CANCER, 2025, 200
  • [39] Clinical outcomes of nab-paclitaxel for advanced or relapsed non-small cell lung cancer patients
    Manabe, Saki
    Murakami, Shuji
    Kondo, Tetsuro
    Saito, Haruhiro
    Yamada, Kouzo
    ANNALS OF ONCOLOGY, 2015, 26 : 124 - 124
  • [40] Real-world experience with FOLFIRINOX and gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in Japan
    Maeda, O.
    Yokoyama, Y.
    Yamaguchi, J.
    Ota, A.
    Matsuoka, A.
    Morita, S.
    Inoue, M.
    Mizutani, T.
    Shimokata, T.
    Urakawa, H.
    Mitsuma, A.
    Nagino, M.
    Ando, Y.
    ANNALS OF ONCOLOGY, 2017, 28 : 69 - 69
12345